Autotaxin (ATX) was first identified as an autocrine motility-stimulating factor, isolated from the supernatant of highly metastatic melanoma cells. By catalyzing the hydrolysis of lysophosphatidylcholine (LPC) to lysophosphatidic acid (LPA), this molecule creates a signaling axis which is essential for vascular and neural development.
ATX-LPA signaling axis has been implicated in a great variety of physiological and pathological processes, including lymphocyte homing pulmonary fibrosis, neuropathic pain, cardiovascular disease, cholestatic pruritus, and tumor progression.
At the embryonic development stage, ATX deficient embryos exhibit defective vascular homeostasis and aberrant neuronal system development.
In adult life, ATX is highly expressed in the adipose tissue and has been implicated in diet-induced obesity and glucose homeostasis with multiple implications in metabolic disorders.
ATX is widely expressed, with the highest mRNA levels detected in the brain, spinal cord, ovary, lung, intestine, and kidney. Dysregulation of autotaxin or the LPA receptors can also lead to hyperproliferation, which may contribute to oncogenesis and metastasis.
ImmunoDiagnostics has developed a series of products of Autotaxin, including human and mouse bioactive recombinant proteins from HEK293 cells, polyclonal antibodies and ELISA kits.